Background: In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for global health status, physical functioning, dyspnea, and cough favored sotorasib over docetaxel. Here, we report sotorasib's additional impact on quality of life (QOL)., Methods: In CodeBreaK 200, 345 patients who had progressed after prior therapy received sotorasib (960 mg orally daily) or docetaxel (75 mg/m 2 intravenously every 3 weeks). Validated questionnaires captured patients' perception of their QOL and symptom burden for key secondary and exploratory PRO endpoints, including the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Quality-of-life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13), question GP5 from the Functional Assessment of Cancer Therapy Tool General Form (FACT-G GP5), PRO-Common Terminology Criteria for Adverse Events (PRO-CTCAE), and 5-level EuroQOL-5 dimensions (EQ-5D-5L) including visual analog scale (EQ-5D VAS). Change from baseline to week 12 was assessed with generalized estimating equations for ordinal outcomes., Results: Patients receiving sotorasib were less bothered by treatment side effects than those receiving docetaxel (odds ratio [OR] 5.7) and experienced symptoms at lower severity (pain: OR 2.9; aching muscles: OR 4.4; aching joints: OR 4.2; mouth or throat sores: OR 4.3). Further, patients' symptoms interfered less with usual/daily activities (pain: OR 3.2; aching muscles: OR 3.9; aching joints: OR 10.7). QOL remained stable with sotorasib but worsened with docetaxel (change from baseline in EQ-5D VAS score: 1.5 vs -8.4 at cycle 1 day 5 and 2.2 vs -5.8 at week 12)., Conclusions: Patients receiving sotorasib reported less severe symptoms than those receiving docetaxel. In addition to improving clinical efficacy outcomes, sotorasib maintained QOL versus docetaxel, suggesting sotorasib may be a more tolerable treatment option for patients with pretreated, KRAS G12C-mutated advanced NSCLC., Competing Interests: Declaration of competing interest David M. Waterhouse received consulting fees from Bristol Myers Squibb (BMS), Amgen, Janssen, Merck, Fresenius Kabi, and Novartis; received honoraria from BMS, AstraZeneca, Amgen, Janssen, EMD Serono, Fresenius Kabi, and Sanofi; received support to attend meetings and/or travel from BMS and Amgen; and participated on a data safety monitoring board or advisory board for BMS, AstraZeneca, AbbVie, Amgen, Janssen, Eisai, EMD Serono, Merck, Pfizer, Fresenius Kabi, Sanofi, Astellas, Gilead, Takeda, Daiichi, and Bayer. Sacha Rothschild received grants or research support from AstraZeneca, Merck Serono, Roche Pharma, and Amgen; received consulting fees from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck KG, MSD, Novartis, Otsuka, Pfizer, PharmaMar, Roche Pharma, Roche Diagnostics, Sanofi Aventis, and Takeda; received honoraria from Roche Pharma, BMS, AstraZeneca, Amgen, MSD Oncology, Novartis, Roche Diagnostics, and Takeda; received payment for expert testimony from Roche, AstraZeneca, and BMS; received support for attending meetings and/or travel from Roche Pharma, Eli Lilly, BMS, Amgen, AstraZeneca, and MSD; participated on a data safety monitoring board or advisory board for Roche Pharma; and is the vice president of the Swiss Group for Clinical Cancer Research (SAKK) and elected member of the Swiss Federal Drug Commission (Federal Health Office). Christophe Dooms has nothing to disclose. Bertrand Mennecier received honoraria from Amgen, Roche, AstraZeneca, Pharma Mar, Eli Lilly, BMS, MSD, Sanofi, Takeda, and Pfizer; and received support for attending meetings and/or travel from MSD, Roche, BMS, AstraZeneca, and Takeda. Farastuk Bozorgmehr received grant/research support from Roche and AstraZeneca; received honoraria from Novocure, Daiichi Sankyo, GSK, and AstraZeneca, received support for attending meetings and/or travel from Janssen; and participated in a data safety monitoring board or advisory board for Amgen, AstraZeneca, Daiichi Sankyo, and Janssen. Margarita Majem received consulting fees from AstraZeneca, Roche, MSD, Janssen, and Sanofi; received honoraria from MSD, Roche, AstraZeneca, Casen Recordati, Takeda, and Helsinn; received support for attending meetings and/or travel from MSD, Pfizer, Roche, and AstraZeneca, and is the vice president of ICAPEM and a board member of AEC Barcelona. Michel M. van den Heuvel participated on a data safety monitoring board or advisory board for Amgen. Helena Linardou received payment or honoraria for lectures and/or speakers bureaus from Roche, AstraZeneca, Pfizer, BMS, MSD, Novartis, Amgen, and GSK; received support for attending meetings and/or travel from Pfizer and Roche; participated on a data safety monitoring board or advisory board for Roche, AstraZeneca, MSD, BMS, Novartis, Pfizer, and Amgen; and held unpaid positions in non-profit organizations, including president of a scientific committee in the Hellenic Cooperative Oncology Group and board member for Hellenic Foundation of Cancer Research, FairLife Lung Cancer, and W4O-Hellas. Byoung Chul Cho received grant/research support from MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GI Innovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Oncology, CJ Bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, Bridge Biotherapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, J INTS BIO, Hanmi, CHA Bundang Medical Center, and Vertical Bio AG. Rachel Roberts-Thomson received royalties from Champions Oncology, Crown Bioscience, Imagen, and PearlRiver Bio GmbH; received consulting fees from Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus Therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, MedPacto, Blueprint Medicines, RaND Bio, and Hanmi; received honoraria from ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Oncology, Korean Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group, Novartis, MSD, The Chinese Thoracic Oncology Society, and Pfizer; participated on a scientific advisory board for Kanaph Therapeutics, Bridge Biotherapeutics, Cyrus Therapeutics, Guardant Health, Oscotec Inc, J INTS Bio, Therapex Co., Ltd, Gilead, and Amgen; was a board member for J INTS BIO; owned stock in TheraCanVac Inc, Gencurix Inc, Bridge Biotherapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., and J INTS BIO; was employed by Yonsei University Health System and is a founder of DAAN Biotherapeutics. Kentaro Tanaka received consulting fees from Pfizer and received honoraria from Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Takeda Pharmaceutical, Novartis, Ono Pharmaceutical, Daiichi Sankyo, Merck, MSD, and BMS. Normand Blais received consulting and speakership fees from Amgen. Gustavo Schvartsman received consulting fees from AstraZeneca, BMS, Merck, Sharp & Dome, and Daiichi Sankyo; received honoraria from Roche, Amgen, Adiu, and Pfizer; and received support for attending meetings and/or travel from Merck, Sharp & Dome and Daiichi Sankyo. Karin Holmskov Hansen participated in clinical trial safety meetings for MSD and Incyte (not paid) and was head of the Danish Oncology Group until February 2023 (not paid) and a member of the Expert Committee under the Danish Medicines Council (not paid). Izabela Chmielewska received consulting honoraria from Amgen; and received speakership fees from Amgen, BMS, Takeda, Roche, and MSD. Martin D. Forster received grant/research support from Cancer Research UK Early Detection Committee Program Grant, Bristol Myers Squibb Research Grant, NIHR RfPB Grant, Cancer Research UK Science Committee Multidisciplinary Project Award, Merck Educational Grant, MSD Educational Grant, Cancer Research UK Science Committee Multidisciplinary Project Award, MRC BMC:DPFS Grant Award, and Boehringer Ingelheim Educational Grant and received consulting fees from Amgen and participated in an Advisory Board for Amgen. Christina Giannopoulou is an employee of Amgen Europe GmbH and holds stock in Amgen. Björn Stollenwerk is an employee of Amgen Europe GmbH and holds stock in Amgen. Cynthia C. Obiozor is an employee of and holds stock in Amgen. Yang Wang is an employee of and holds stock in Amgen.Silvia Novello received honoraria from AstraZeneca, Amgen, Thermo Fisher, MSD, Novartis, Sanofi, Roche, Pfizer, Takeda, and Janssen and participated on a data safety monitoring board or advisory board from Pfizer, AstraZeneca, Sanofi, Jannsen, and Daiichi., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)